Publications by authors named "K Cusi"
Background & Aims: Lanifibranor is a pan-PPAR agonist that improves glucose/lipid metabolism and reverses steatohepatitis and fibrosis in adults with MASH. We tested its effect on insulin resistance at the level of different target tissues in relationship to change in intrahepatic triglyceride (IHTG) content.
Methods: This phase 2, single center, study randomized (1:1) 38 patients with T2D and MASLD to receive lanifibranor 800 mg or placebo for 24 weeks.
Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a public health threat as it affects approximately 38% of the adult population worldwide, with its prevalence rising in step with that of obesity and type 2 diabetes. Beyond the implications of MASLD for liver health, it is also associated with cardiovascular and vascular dysfunction. Although the many shared risk factors and common metabolic milieu might indicate that cardiovascular disease and MASLD are discrete outcomes from common systemic pathogeneses, a growing body of evidence has identified a potential causal relationship between MASLD and coronary artery disease, which is the leading cause of morbidity and mortality in people with MASLD and all-cause mortality worldwide.
View Article and Find Full Text PDFArticle Synopsis
- MRI biomarkers like iron corrected T1 (cT1) and liver fat content (LFC) are promising noninvasive alternatives to liver biopsies, showing potential associations with liver disease improvement.
- A study analyzed data from 150 participants in clinical trials, revealing that responders (those who had a resolution of steatohepatitis) demonstrated significantly greater reductions in cT1 and LFC compared to non-responders.
- These findings suggest that significant changes in these MRI markers can help predict histological improvements in liver health following treatment, highlighting their potential utility in clinical settings.